EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

P2Y12 adenosine receptor inhibitors preloading among patients with non‐ST‐elevation acute coronary syndromes; insights from a nationwide multicenter registry

Ziad Arow iD, Hezzy Shmueli, Edward Koifman iD, Rami Barashi iD, Abid Assali, Luham Mahajna, Katia Orvin iD, Roy Beigel, Yigal Abramowitz, Gal Tsaban

Catheterization and Cardiovascular Interventions · 2024

DOI: 10.1002/ccd.31143 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2024. Verfasst von Ziad Arow und 9 weiteren Autor:innen. Beteiligte Einrichtung: Meir Medical Center, Heart Institute, Kfar Saba, Israel. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Non-ST Elevated Myocardial Infarction, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Israeli Heart Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The safety and efficacy of treatment with P2Y12 adenosine‐diphosphate receptor inhibitors (P2Y12‐RI) before coronary angiography among patients with non‐ST‐segment elevation acute coronary syndromes (NSTEACS) are questionable.

Aims

To assess the pretreatment rate with P2Y12‐RI and its association with ischemic and bleeding risks among patients with NSTEACS.

Methods

The study comprised patients with NSTEACS referred for coronary angiography and included in the Acute Coronary Syndrome Israeli Surveys between 2013 and 2021. Patients were divided into two groups according to the timing of P2Y12‐RI loading concerning coronary angiography: pretreatment and posttreatment. The primary endpoints were 30‐day major adverse cardiovascular events (MACE; composite of cardiovascular mortality, myocardial infarction, stroke, stent thrombosis, and urgent revascularization) and 1‐year all‐cause mortality.

Results

Of 3076 patients, 2423 (78.8%) received pretreatment with a P2Y12‐RI, and 653 (21.2%) received P2Y12‐RI posttreatment. Prasugrel and ticagrelor were used more in the posttreatment group compared to the pretreatment group (16% vs. 6% and 38% vs. 25%, respectively, p < 0.001 for both). No difference was observed in the rate of 30‐day MACE comparing pretreatment and posttreatment (5.3% vs. 2.2%, respectively, p = 0.62). A sensitivity analysis of 30‐day MACE among patients from the 2021 survey demonstrated similar results (2.5% in the posttreatment group vs. 8.0% in the pretreatment group, p = 0.13). There were no differences in 1‐year all‐cause mortality rates between the pretreatment and posttreatment groups (4.8% vs. 3.8%, p = 0.31).

Conclusions

Among patients with NSTEACS referred for an invasive strategy, the P2Y12‐RI posttreatment strategy was associated with similar 30‐day and 1‐year MACE as the pretreatment strategy. These large‐scale, multicenter, real‐world data provide reassurance on the safety and efficacy of delaying P2Y12‐IR until after coronary stratification to improve clinical decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeNon-ST Elevated Myocardial InfarctionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsAgedAged, 80 and overFemaleHumansMaleMiddle AgedCoronary AngiographyHemorrhageIsraelRegistriesRisk AssessmentRisk FactorsTicagrelorTime FactorsTreatment Outcome

Stichwörter der Autor:innen

ACS—acute coronary syndromeAntiplatelet pretreatmentMI—myocardial infarctionP2Y12‐RI ‐ P2Y12 adenosine‐diphosphate receptor inhibitor

Substanzen

Platelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsTicagrelor

Autor:innen und Institutionen

  • Meir Medical Center, Heart Institute, Kfar Saba, Israel.
  • Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
  • Department of Cardiology, Soroka University Medical Center, Beersheva, Israel.
  • Faculty of Health Sciences, Ben Gurion University of the Negev, Beersheva, Israel.
  • Emek Medical Center, Heart Institute, Afula, Israel.
  • Rappaport Faculty of Medicine, Technion, Haifa, Israel.

ORCID-Profile: Ziad Arow, Edward Koifman, Rami Barashi, Katia Orvin

Förderung

  • Israeli Heart Society

Zitieren

APA

Arow, Z., Shmueli, H., Koifman, E., Barashi, R., Assali, A., Mahajna, L., Orvin, K., Beigel, R., Abramowitz, Y., & Tsaban, G. (2024). P2Y12 adenosine receptor inhibitors preloading among patients with non‐ST‐elevation acute coronary syndromes; insights from a nationwide multicenter registry. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31143

Vancouver

Arow Z, Shmueli H, Koifman E, Barashi R, Assali A, Mahajna L, et al. P2Y12 adenosine receptor inhibitors preloading among patients with non‐ST‐elevation acute coronary syndromes; insights from a nationwide multicenter registry. Catheterization and Cardiovascular Interventions. 2024. doi:10.1002/ccd.31143

BibTeX
@article{Arow2024,
  author = {Arow, Ziad and Shmueli, Hezzy and Koifman, Edward and Barashi, Rami and Assali, Abid and Mahajna, Luham and Orvin, Katia and Beigel, Roy and Abramowitz, Yigal and Tsaban, Gal},
  title = {P2Y12 adenosine receptor inhibitors preloading among patients with non‐ST‐elevation acute coronary syndromes; insights from a nationwide multicenter registry},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2024},
  doi = {10.1002/ccd.31143}
}
Kostenlos starten →